{"id":280,"date":"2011-02-02T17:22:33","date_gmt":"2011-02-03T00:22:33","guid":{"rendered":"http:\/\/ipmetrics.net\/blog\/?p=280"},"modified":"2011-02-02T17:22:33","modified_gmt":"2011-02-03T00:22:33","slug":"bayer-loses-patent-royalty-claim-on-claim-construction","status":"publish","type":"post","link":"http:\/\/www.ipmetrics.net\/blog\/litigation\/case-law\/bayer-loses-patent-royalty-claim-on-claim-construction\/","title":{"rendered":"Bayer loses patent royalty claim on claim construction"},"content":{"rendered":"<p>Europe\u2019s largest drug and chemical maker,\u00a0Bayer AG,\u00a0lost another effort to collect patent royalties from a competitor. \u00a0Bayer claims certain arthritis drugs violate a patent for antibodies against tumor necrosis factor, or TNF, an immune-cell protein linked to inflammation.<\/p>\n<p>This time around,\u00a0Bayer, which sued in 2009, conceded that Johnson &amp; Johnson&#8217;s <em>Simponi<\/em> product isn\u2019t infringing its patent under an interpretation of \u201chuman monoclonal antibodies\u201d issued by a federal judge last month. \u00a0Bayer\u2019s claim to royalties on\u00a0sales of the rheumatoid arthritis drug\u00a0, terminated last friday, could be revived if it wins its appeal of the ruling.<\/p>\n<p>Earlier this month, Bayer made the same concession in a suit against Abbott Laboratories, maker of the arthritis drug Humira.<\/p>\n<p><a title=\"Open Report\" href=\"http:\/\/www.bloomberg.com\/news\/2011-02-01\/bayer-nespresso-interval-al-jazeera-intellectual-property.html?cmpid=msnmoney\" target=\"_blank\">Bloomberg <\/a> reported\u00a0Oliver Renner, a Bayer spokesman, said after the Abbott ruling that the concesion was \u201ca procedural step in order to allow a quick appeal\u201d of the earlier determination on the definition of the phrase. \u00a0Moreover, the prestigious business publication reported\u00a0Brian Kenney, a spokesman for J&amp;J\u2019s Centocor Ortho Biotech unit, saying the company agreed\u00a0\u201c&#8230;with the judge\u2019s ruling related to the claim construction and remain confident that it will be sustained on appeal\u201d .<\/p>\n<p>The case is Bayer Healthcare LLC v. Centocor Ortho Biotech Inc., 09cv11362, and the Abbott case is\u00a0Abbott Laboratories v. Bayer Healthcare LLC, 09cv40002, U.S. District Court for the District of Massachusetts (Worcester).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Europe\u2019s largest drug and chemical maker, Bayer AG, lost another effort to collect patent royalties from a competitor.  Bayer claims certain arthritis drugs violate a patent for antibodies against tumor necrosis factor, or TNF, an immune-cell protein linked to inflammation<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[3,10,11,17,19],"tags":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","jetpack_shortlink":"https:\/\/wp.me\/p2xROl-4w","_links":{"self":[{"href":"http:\/\/www.ipmetrics.net\/blog\/wp-json\/wp\/v2\/posts\/280"}],"collection":[{"href":"http:\/\/www.ipmetrics.net\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.ipmetrics.net\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.ipmetrics.net\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.ipmetrics.net\/blog\/wp-json\/wp\/v2\/comments?post=280"}],"version-history":[{"count":0,"href":"http:\/\/www.ipmetrics.net\/blog\/wp-json\/wp\/v2\/posts\/280\/revisions"}],"wp:attachment":[{"href":"http:\/\/www.ipmetrics.net\/blog\/wp-json\/wp\/v2\/media?parent=280"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.ipmetrics.net\/blog\/wp-json\/wp\/v2\/categories?post=280"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.ipmetrics.net\/blog\/wp-json\/wp\/v2\/tags?post=280"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}